PLX
Protalix Biotherapeutics Inc
NYSE MKT: PLX · HEALTHCARE · BIOTECHNOLOGY
$2.02
+3.06% today
Updated 2026-05-06
Market cap
$170.81M
P/E ratio
—
P/S ratio
3.24x
EPS (TTM)
$-0.08
Dividend yield
—
52W range
$1 – $3
Volume
0.9M
Protalix Biotherapeutics Inc (PLX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
1 of 8
Last 8 quarters
Avg EPS surprise
-96.8%
Last 4 quarters
Revenue YoY growth
-49.9%
Most recent quarter
EPS YoY growth
-177.8%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-7.6%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-13.1%
2025-11-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-12 | $-0.07 | -300.0% | $2.89 | $2.83 | -2.1% |
| 2025-11-13 | $0.03 | -57.1% | $2.14 | $1.86 | -13.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $0.04 | $-0.07 | -300.0% | $9.12M | -49.9% |
| 2025-09-30 | $0.07 | $0.03 | -57.1% | $17.85M | -0.6% |
| 2025-06-30 | $0.11 | $-0.04 | -136.4% | $15.66M | +16.2% |
| 2025-03-31 | $-0.02 | $-0.05 | -150.0% | $10.11M | +169.8% |
| 2024-12-31 | $0.07 | $0.09 | +28.6% | $18.22M | +73.7% |
| 2024-09-30 | $0.06 | $0.03 | -50.0% | $17.96M | +73.6% |
| 2024-06-30 | $0.02 | $-0.03 | -250.0% | $13.47M | -61.6% |
| 2024-03-31 | $-0.02 | $-0.06 | -200.0% | $3.75M | -60.9% |
| 2023-12-31 | $-0.03 | $-0.07 | -133.3% | $10.49M | — |
| 2023-09-30 | $-0.07 | $-0.04 | +42.9% | $10.35M | — |
| 2023-06-30 | $-0.04 | $0.21 | +625.0% | $35.08M | — |
| 2023-03-31 | $-0.05 | $-0.05 | +0.0% | $9.59M | — |
Frequently asked questions
Has Protalix Biotherapeutics Inc beaten earnings estimates?
Protalix Biotherapeutics Inc has beaten Wall Street EPS estimates in 1 of its last 8 quarterly reports, with an average EPS surprise of -96.8% over the last 2 quarters.
How does PLX stock react to earnings?
PLX stock has moved an average of -7.6% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Protalix Biotherapeutics Inc's revenue growth rate?
Protalix Biotherapeutics Inc reported year-over-year revenue growth of -49.9% in its most recent quarter, with EPS growing -177.8% year-over-year.